Rokit Healthcare Secures U.S. Patent for Multi-organ Bioprinter

Rokit Healthcare is expanding its global competitiveness by achieving patent successes in organ regeneration across the United States, Korea, and China.

On July 28, Rokit Healthcare, an AI-based organ regeneration platform company, announced that it had secured a U.S. patent registration for its multi-organ 3D bioprinter technology at the end of June 2025.

The company added that it had recently completed patent registrations in Korea and China for its tissue regeneration technology using an additive-free low-temperature molding method. This is evaluated as strengthening its cutting-edge global technological competitiveness in the field of AI hyper-personalized organ regeneration platforms.

The company explained that this U.S. patent is for 3D bioprinting technology that can simultaneously print five types of bioinks, laying the technological foundation for directly printing complex organs such as the heart, liver, and pancreas in the operating room. Rokit Healthcare emphasized that it has secured a firm technological advantage as a global first mover in the field of AI hyper-personalized organ regeneration and is pursuing continuous technological advancement.

According to the company, this U.S. patent is for multi-printing technology that can biocompatibly and precisely control and output up to five bioinks, including various cells, growth factors, and extracellular matrix (ECM). It automatically adjusts temperature, pressure, and viscosity for each bioink using an NFC automatic recognition system and implements a bio-incubation environment in a sealed CO₂ chamber. The company highlighted that real-time quality monitoring based on high-magnification cameras automatically detects and controls minute errors in bioprinting, securing the possibility of producing complex high-precision organ tissues such as heart, pancreas, and liver “Just In Surgery,” thereby greatly expanding the application area of AI hyper-personalized patient-specific organ regeneration.

Rokit Healthcare also revealed that it is currently undergoing patent examination in the United States for its tissue regeneration patch manufacturing technology using an “additive-free low-temperature molding” method utilizing autologous tissue, which has recently completed patent registration in Korea and China.

This technology creates human organ regeneration tissue using only hyper-personalized bio-derived materials without external medical additives, with minimal manipulation and “Just In Surgery.” It is expected to contribute to shortening the approval period in the development and approval process of bioprinting organ regeneration in the future, as it complies with the regulations emphasized by the U.S. FDA and European EMA for monitoring cancer occurrence due to stem cell manipulation and ensuring biosafety.

A Rokit Healthcare official stated, “These patented technologies are core technologies that can support the key competitive advantage of a cutting-edge AI hyper-personalized organ regeneration platform beyond simple bioprinting,” adding, “By integrating multi-organ printing technology and low-temperature molding technology to secure various multi-organ platform source technologies, we will lead the paradigm shift in global regenerative medicine and solidify our position as a ‘first mover’ in this field.”